Methotrexate reduces antibody responses to recombinant human α-galactosidase A therapy in a mouse model of Fabry disease

Clinical and Experimental Immunology

Volumn 137, Issue 3, 2004, Pages 496-502

  Garman, Richard D ^a   Munroe, K ^a   Richards, S M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Antibody; Enzyme replacement therapy; Fabry disease; Lysosomal storage disease; Methotrexate; Mouse model

Indexed keywords

ALPHA GALACTOSIDASE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RECOMBINANT HUMAN ALPHA GALACTOSIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODIES; FABRY DISEASE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MODELS, ANIMAL; RECOMBINANT PROTEINS; SPLEEN;

EID: 4344627627     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02567.x     Document Type: Article

References (28)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9:418-35.
2. Richards SM. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders. Clin Appl Immunol Rev 2002; 2:241-53.
3. Kingma W, Rosenberg M, Richards SM. Antibody formation in patients receiving Imiglucerase and impact on safety and clinical response. Gaucher Clin Perspect 1998; 6:8-11.
4. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 1993; 82:1402-9.
5. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Guacher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999; 93:2081-8.
6. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9-16.
7. Desnick RJ, Ioannou YA, Eng CM. Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis for inherited disease. New York: McGraw-Hill, 2001:3733-74.
8. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystem disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann Intern Med 2003; 138:338-46.
9. Wang A, Ioannou Y, Zeidner K et al. Generation of a mouse model with alpha-galactosidase A deficiency. Am J Human Genet 1996; 59:A208.
10. Ioannou Y, Zeidner K, Gordon RE, Desnick R. Fabry disease preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme deficient mice. Am J Human Genet 2001; 68:14-25.
11. Lee K, Lin XY, Zhang K et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13:305-13.
12. Gotlib RW, Bishop DF, Wang AM et al. The entire genomic sequence and cDNA expression of mouse α-galactosidase A. Biochem Molec Med 1996; 57:139-48.
13. Schad VC, Garman RD, Greenstein JL. The potential use of T cell epitopes to alter the immune response. Semin Immunol 1991; 3:217-24.
14. Wauben MH. Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 2000; 20:451-69.
15. Liblau RS, Tisch R, Shokat K et al. Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc Natl Acad Sci USA 1996; 93:3131-6.
16. Switzer S, Wallner BP, Briner TJ, Sunshine GH, Bourque CR, Luqman M. Bolus injection of aqueous antigen leads to a high density of T-cell-receptor ligand in the spleen, transient T-cell activation and anergy induction. Immunology 1998; 94:513-22.
17. + T cells. J Immunol 1999; 163:2592-600.
18. Brooks DA, Kavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Molec Med 2003; 9:450-3.
19. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9:436-63.
20. Hyman LR, Kovacs K, Steinberg AD. Drug-induced tolerance: selective induction with immunosuppressive drugs and their synergistic interaction. Int Arch Allergy Appl Immunol 1975; 48:248-60.
21. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard J-P. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-8.
22. Paillot R, Genestier L, Fournel S, Ferraro C, Miossec P, Revillard J-P. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 1998; 30:2348-50.
23. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 2003; 42:1230-6.
24. Taylor PC. Anti-TNF-alpha therapy for rheumatoid arthritis: an update. Int Med 2003; 42:15-20.
25. Antoni C, Kalden JR. Combination therapy of chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:S73-7.
26. Wagner CL, Schantz A, Barnathan E et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 2003; 112:37-53.
27. Kishnani P, Voit T, Nicolino M et al. Enzyme replacement therapy with recombinant human acid alpha glucosidase (rhGAA) in infantile Pompe disease (IPD): results from a phase 2 study. Pediatr Res 2003; 53:259A.
28. Hunley TE, Corzo D, Dudek M et al. Nephrotic syndrome (NS) complicating recombinant human acid alpha-glucosidase (rhGAA) replacement therapy for Pompe disease. Pediatr Res 2003; 53:532A.